Lynparza Long-Term Responders Likely to have Deficient DNA Repair

Lynparza Long-Term Responders Likely to have Deficient DNA Repair
Long-term, progression-free survival in women with ovarian cancer treated with Lynparza (olaparib) is likely linked to deficient DNA repair mechanisms, particularly those caused by mutations in the BRCA genes. In addition to that finding, the study, "Long-term responders on olaparib maintenance in high-grade serous ovarian cancer: Clinical and molecular characterization," showed that patients who had a complete response to chemotherapy had a better chance of not developing resistance to the treatment. The report was published in the journal Clinical Cancer Research. Because about 70% of women with high-grade serous ovarian cancer relapse despite good responses to initial treatment, researchers are seeking ways to prevent  patients from relapsing. Lynparza is a PARP inhibitor drug that improved progression-free survival — from 4.8 months to 8.4 months — in an earlier trial (NCT01081951), when used as a maintenance treatment after chemotherapy. To assess which characteristics might predict a longer response to the treatment, researchers at the Princess Margaret Cancer Centre in Canada and AstraZeneca, analyzed the features of patients who had not progressed for at least two years. The patients were participating in another clinical trial (NCT00753545), comparing Lynparza with placebo. Researchers compared 37 patients with a long-
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *